Private company

HUMANIGEN, INC

American pharmaceutical preparations company, incorporated in Delaware.

Last updated Oct 18, 2026.

Overview

IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE²
Business address830 Morris Turnpike, 4Th Floor, Short Hills, Nj 07078²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-2716.9%Operating margin³

-2813.4%Net margin³

-30.1%Revenue growth, 2022³

Where the money goes

Where each dollar of revenue went, fiscal 2022

Research and development

Research and development95¢$55.2M
Interest5¢$2.9M

Out of $2.5M in revenue.³ The company lost money this year.

Financial statements

Revenue⁴³$2.5M in 2022+706% since 2020

Operating income⁵⁶⁷⁸⁴³-$68.3M in 2022+263% since 2016

Net income⁵⁶⁷⁸⁴³-$70.7M in 2022+162% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Revenue					$312.0K⁴	$3.6M³	$2.5M³
Research and development	$10.4M⁵	$11.2M⁶	$2.2M⁷	$2.6M⁸	$72.7M⁴	$213.1M³	$55.2M³
Operating income	-$18.8M⁵	-$19.0M⁶	-$11.3M⁷	-$8.9M⁸	-$88.2M⁴	-$232.8M³	-$68.3M³
Interest	$131.0K⁵	$3.1M⁶	$852.0K⁷	$1.3M⁸	$1.3M⁴	$2.3M³	$2.9M³
Income tax						$21.6M⁴
Net income	-$27.0M⁵	-$22.0M⁶	-$12.0M⁷	-$10.3M⁸	-$89.5M⁴	-$236.6M³	-$70.7M³
Earnings per share						-$4.04³	-$0.79³
Earnings per share (diluted)						-$4.04³	-$0.79³

Total assets⁵⁶⁷⁸⁴³$11.2M in 2022+137% since 2016

Total liabilities⁵⁶⁷⁸⁴³$58.0M in 2022+537% since 2016

Shareholders’ equity⁶⁷⁸⁴³-$46.8M in 2022+968% since 2016

Cash⁶⁷⁸⁴³$10.2M in 2022+238% since 2016

Long-term debt⁷³$25.0M in 2021+285% since 2019

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash	$3.0M⁶	$737.0K⁶	$814.0K⁷	$143.0K⁸	$67.7M⁴	$70.0M³	$10.2M³
Current assets	$4.5M⁵	$1.6M⁶	$1.3M⁷	$452.0K⁸	$68.2M⁴	$71.0M³	$11.1M³
Total assets	$4.7M⁵	$1.7M⁶	$1.4M⁷	$523.0K⁸	$68.3M⁴	$71.1M³	$11.2M³
Current liabilities	$7.8M⁵	$24.7M⁶	$8.3M⁷	$13.6M⁸	$20.4M⁴	$68.7M³	$56.2M³
Long-term debt				$6.5M⁷		$25.0M³
Total liabilities	$9.1M⁵	$26.0M⁶	$9.5M⁷	$14.8M⁸	$22.8M⁴	$94.7M³	$58.0M³
Shareholders’ equity	-$4.4M⁶	-$24.3M⁷	-$8.1M⁸	-$14.3M⁴	$45.5M³	-$23.7M³	-$46.8M³
Shares outstanding	15.0M shares⁵	14.9M shares⁶	109.9M shares⁷	22.8M shares⁸	51.6M shares⁴	64.0M shares³	119.1M shares³

Cash from operations⁵⁶⁷⁸⁴³-$76.7M in 2022+266% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash from operations	-$21.0M⁵	-$14.2M⁶	-$6.2M⁷	-$4.0M⁸	-$69.9M⁴	-$184.0M³	-$76.7M³
Capital spending
Free cash flow

Compare HUMANIGEN, INC with another company

Leadership

Who has led HUMANIGEN, INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Chief financial officer

Chief operating officer

Timothy E. Morris2020–2022

201520202025

Chief executive officerCameron Durrant Jul 5, 2016 to Jul 29, 2022¹²
Chief executive officerDavid Pritchard Aug 10, 2012 to Jan 22, 2014¹³
ChairCameron Durrant Jul 5, 2016 to Jul 5, 2016¹²
ChairRon Martell May 28, 2015 to Oct 28, 2015¹⁴
Chief financial officerTimothy E. Morris Sep 22, 2020 to Jul 29, 2022¹⁵
Chief financial officerJ. Gregory Jester Mar 7, 2018 to Jan 28, 2019¹⁶
Chief financial officerDavid L. Tousley Oct 14, 2016 to Feb 22, 2017¹⁷
Chief financial officerHerb Cross Oct 23, 2013 to Nov 10, 2015¹⁸
Chief financial officerJeffrey H. Cooper Aug 10, 2012 to May 2, 2013¹⁹
Chief operating officerTimothy E. Morris Sep 22, 2020 to Jul 29, 2022¹⁵

Board members and other officers (34)

Chief Medical OfficerAdrian Kilcoyne Apr 22, 2021 to Jul 29, 2022²⁰
OfficerDavid L. Tousley Jul 10, 2020 to Sep 22, 2020²¹
Chief Commercial OfficerP. Jordan Edward Sep 3, 2020 to Jul 29, 2022²²
Chief Scientific OfficerDale Chappell Sep 22, 2020 to Oct 20, 2023²³
Chief Scientific OfficerMorgan Lam Sep 15, 2016 to Feb 22, 2017²⁴
Chief Scientific OfficerGeoffrey Thomas Yarranton Aug 10, 2012 to Feb 18, 2015²⁵
Chief Medical OfficerNestor Molfino Aug 10, 2012 to Jan 22, 2014²⁶
Board memberJohn Hohneker Oct 20, 2021 to Jul 29, 2022²⁷
Board memberYili Kevin Xie Oct 20, 2021 to Jul 29, 2022²⁸
Board memberCheryl Buxton Dec 16, 2019 to Jul 29, 2022²⁹
Board memberRainer J. Boehm Feb 22, 2018 to Jul 29, 2022³⁰
Board memberRobert G. Savage Mar 13, 2018 to Apr 7, 2020³¹
Board memberCameron Durrant Jan 15, 2016 to Jul 29, 2022³²
Board memberRonald Barliant Jan 15, 2016 to Jul 29, 2022³³
Board memberDale Chappell Jul 11, 2016 to Oct 20, 2023³⁴
Board memberTimothy E. Morris Jul 11, 2016 to Mar 13, 2018³⁵
Board memberEzra M. Friedberg Jul 12, 2016 to Sep 15, 2016³⁶
Board memberRon Martell Apr 23, 2015 to Apr 27, 2015³⁷
Board memberMichael Wayne Harrison Dec 1, 2015 to Dec 18, 2015³⁸
Board memberThomas Edward Fernandez Dec 1, 2015 to Dec 18, 2015³⁹
Board memberAnthony R. Chase Dec 7, 2015 to Dec 7, 2015⁴⁰
Board memberDavid Moradi Dec 17, 2015 to Dec 18, 2015⁴¹
Board memberRobert Baffi Dec 1, 2014 to Jul 14, 2015⁴²
Board memberBryan Lawlis V. Aug 15, 2013 to Jun 20, 2014⁴³
Board memberAlsup Laurie Smaldone Oct 23, 2013 to Jul 14, 2015⁴⁴
Board memberBrigitte Smith Aug 10, 2012 to Aug 21, 2013⁴⁵
Board memberDavid Pritchard Aug 10, 2012 to Jan 22, 2014¹³
Board memberDennis Henner Aug 10, 2012 to May 3, 2013⁴⁶
Board memberGary A. Lyons Aug 10, 2012 to Jul 14, 2015⁴⁷
Board memberJames Healy Aug 10, 2012 to May 2, 2013⁴⁸
Board memberTed W. Love Aug 10, 2012 to Jul 14, 2015⁴⁹
Board memberRaymond M. Withy Aug 13, 2012 to Jul 14, 2015⁵⁰
Board memberDenise Gilbert Aug 15, 2012 to Jul 14, 2015⁵¹
General counselDonald Joseph Aug 1, 2013 to Feb 18, 2015⁵²

Former names

KALOBIOS PHARMACEUTICALS INCJun 4, 2004 to Jul 17, 2017²

Timeline

Jul 5, 2016New chief executive Cameron Durrant becomes CEO¹²
Aug 10, 2012New chief executive David Pritchard becomes CEO¹³

Filings

100 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 30 major events, 44 insider forms, 9 large holders, 9 other. The latest 20:

Jan 8, 20248-K EDGAR
Oct 20, 20234 EDGAR
Oct 12, 202325-NSE EDGAR
Sep 14, 20238-K EDGAR
Aug 14, 2023NT 10-Q EDGAR
Jul 25, 20238-K EDGAR
May 15, 202310-Q EDGAR
Apr 25, 202310-K/A AMENDMENT NO. 1 EDGAR
Apr 19, 20238-K EDGAR
Apr 6, 20238-K EDGAR
Mar 30, 202310-K EDGAR
Mar 13, 20238-K EDGAR
Mar 2, 20238-K EDGAR
Feb 24, 20238-K EDGAR
Feb 1, 2023SC 13G/A EDGAR
Dec 22, 20228-K EDGAR
Nov 14, 202210-Q EDGAR
Nov 14, 20228-K EDGAR
Oct 6, 20228-K EDGAR
Sep 29, 20228-K EDGAR

The 100 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 9 such filings since October 2021:

Feb 1, 2023SC 13G/A
Aug 10, 2022SC 13G/A
May 9, 2022SC 13G
Mar 17, 2022SC 13D/A
Feb 14, 2022SC 13G/A
Feb 4, 2022SC 13G
Jan 10, 2022SC 13G/A
Dec 30, 2021SC 13G
Oct 12, 2021SC 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARHUMANIGEN, INC filings on SEC EDGAR
2
SEC EDGARHUMANIGEN, INC filings on SEC EDGAR
3
SEC EDGARHUMANIGEN, INC 10-K for fiscal 2022
4
SEC EDGARHUMANIGEN, INC 10-K for fiscal 2020
5
SEC EDGARHUMANIGEN, INC 10-K for fiscal 2016
6
SEC EDGARHUMANIGEN, INC 10-K for fiscal 2017
7
SEC EDGARHUMANIGEN, INC 10-K for fiscal 2018
8
SEC EDGARHUMANIGEN, INC 10-K for fiscal 2019
9
SEC EDGARHUMANIGEN, INC 10-Q for fiscal 2022
10
SEC EDGARHUMANIGEN, INC 10-Q for fiscal 2022
11
SEC EDGARHUMANIGEN, INC 10-Q for fiscal 2023
12
SEC EDGARCameron Durrant, Chief executive officer
13
SEC EDGARDavid Pritchard, Chief executive officer
14
SEC EDGARRon Martell, Chair
15
SEC EDGARTimothy E. Morris, Chief financial officer
16
SEC EDGARJ. Gregory Jester, Chief financial officer
17
SEC EDGARDavid L. Tousley, Chief financial officer
18
SEC EDGARHerb Cross, Chief financial officer
19
SEC EDGARJeffrey H. Cooper, Chief financial officer
20
SEC EDGARAdrian Kilcoyne, Chief Medical Officer
21
SEC EDGARDavid L. Tousley, Officer
22
SEC EDGARP. Jordan Edward, Chief Commercial Officer
23
SEC EDGARDale Chappell, Chief Scientific Officer
24
SEC EDGARMorgan Lam, Chief Scientific Officer
25
SEC EDGARGeoffrey Thomas Yarranton, Chief Scientific Officer
26
SEC EDGARNestor Molfino, Chief Medical Officer
27
SEC EDGARJohn Hohneker, Board member
28
SEC EDGARYili Kevin Xie, Board member
29
SEC EDGARCheryl Buxton, Board member
30
SEC EDGARRainer J. Boehm, Board member
31
SEC EDGARRobert G. Savage, Board member
32
SEC EDGARCameron Durrant, Board member
33
SEC EDGARRonald Barliant, Board member
34
SEC EDGARDale Chappell, Board member
35
SEC EDGARTimothy E. Morris, Board member
36
SEC EDGAREzra M. Friedberg, Board member
37
SEC EDGARRon Martell, Board member
38
SEC EDGARMichael Wayne Harrison, Board member
39
SEC EDGARThomas Edward Fernandez, Board member
40
SEC EDGARAnthony R. Chase, Board member
41
SEC EDGARDavid Moradi, Board member
42
SEC EDGARRobert Baffi, Board member
43
SEC EDGARBryan Lawlis V., Board member
44
SEC EDGARAlsup Laurie Smaldone, Board member
45
SEC EDGARBrigitte Smith, Board member
46
SEC EDGARDennis Henner, Board member
47
SEC EDGARGary A. Lyons, Board member
48
SEC EDGARJames Healy, Board member
49
SEC EDGARTed W. Love, Board member
50
SEC EDGARRaymond M. Withy, Board member
51
SEC EDGARDenise Gilbert, Board member
52
SEC EDGARDonald Joseph, General counsel